Methotrexate adjuvants to reduce toxicity and methods for using the same
US9382287B2 · kind B2 · utility
3Cited by
9References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 6, 2014 |
| Grant date | Jul 5, 2016 |
| Priority date | — |
| Expiry date | Oct 9, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.